In this article
NiceRx distinguishes the first month from the continuing price on its weight-loss page. If you are searching for an alternative because the next payment is higher, the useful baseline is the ongoing rate and what it includes.
The page describes a self-pay program with medication, provider access, and shipping included. This guide compares that structure with prepaid packages, separate memberships, and other offers whose low starting figures need additional explanation.
Compare continuing treatment costs and order-stage cancellation rules before changing providers to obtain another introductory price. CoreAge Rx holds the first sponsored position; that does not establish that it best meets every criterion.
What to know first
- Compare continuing treatment costs and order-stage cancellation rules before changing providers to obtain another introductory price.
- CoreAge Rx is the first listing through a disclosed commercial arrangement.
- Confirm the proposed product, care arrangement, and complete written payment terms.
How this shortlist was selected
CoreAge Rx is number one because it is our featured commercial partner. That position is predetermined by our commercial relationship, and we may earn compensation through its links. Other entries illustrate relevant care and payment models; their order is not a ranking of medication quality, safety, or patient outcomes.
Compare continuing treatment costs and order-stage cancellation rules before changing providers to obtain another introductory price. We used the provider documents linked beside each entry, checked September 21, 2026. We did not purchase treatment, test private accounts, audit every license, or measure response times. The product and current written quote for your own care still need confirmation. Read our review method.
01. CoreAge Rx — featured partner
Our first sponsored listing offers a self-pay comparison without a separate advertised membership. Ask for the regular price and full payment term before putting it beside NiceRx’s ongoing rate.
The current sale page advertises semaglutide from $99 per month and tirzepatide from $149 per month, with no membership fee. Those are advertised starting figures, not a personalized checkout quote. The plan length and total amount due must be read alongside the monthly equivalent.
The sale page says CoreAge works with U.S. compounding pharmacies and describes 503A facilities. A category of pharmacy is not a substitute for the name, address, and state license of the pharmacy filling your own prescription. Request that information before deciding.
Continue with our CoreAge Rx review and pricing details.
02. Brightmeds
A comparison for a listed single-month charge versus a campaign bundle. Verify campaign eligibility and renewal rather than assuming a seasonal figure is permanent.
The Brightmeds Summer Special page lists semaglutide at $297 for three months ($99 per month), or $129 for a single month. Tirzepatide is $357 for three months ($119 per month), or $149 for a single month. These are dated campaign offers.
Confirm whether the campaign remains available for your prescription and what the renewal costs. The three-month equivalent is not the charge for the separately listed single-month option.
Check the official Brightmeds program page for the current offer and conditions. Our Brightmeds alternatives comparison examines other care models.
03. Ivy Rx
An alternative whose starting offer needs a more detailed treatment quote. It illustrates why the lowest headline alone cannot settle a continuing-cost comparison.
IvyRx’s weight-loss page displays a $77 starting offer, including a separate microdosing offer. The page does not establish one complete ongoing price and payment term for every GLP-1 plan.
Request the exact treatment, amount due today, refill price, and included care. Do not apply a microdosing price or a promotional starting figure to a different prescription.
Check the official Ivy Rx program page for the current offer and conditions. Our Ivy Rx alternatives comparison examines other care models.
04. OrderlyMeds
Separates starter and continuing treatment. Its new-customer package needs the same scrutiny as any attempt to replace an ongoing price with another introductory offer.
The pricing page advertises a two-month starter package at $149 total for compounded semaglutide and $299 total for compounded tirzepatide. Those totals correspond to $74.50 and $149.50 per month, even though the display rounds the monthly headlines. The offer is labeled for new customers.
OrderlyMeds describes text-based provider review and pharmacy preparation after approval. Its stated shipping time is an estimate and should not be confused with guaranteed prescribing or a tested turnaround time.
Continue with our OrderlyMeds review and pricing details.
05. Mochi Health
Uses membership plus medication, which should be added together before comparing with an inclusive NiceRx quote. The medication component can vary with the prescription.
Mochi advertises a $39 first membership month for eligible new subscribers and a $79 ongoing monthly membership. Its August 2026 pricing explanation describes dose-based compounded semaglutide prices of $60–$99 and tirzepatide prices of $90–$199, with medication billed separately.
Mochi’s pricing article says its transition to dose-based prices did not change the pharmacies or additives for the plans discussed. It does not identify your personal dispensing pharmacy. Confirm the pharmacy and complete formulation shown in your own care plan.
Continue with our Mochi Health review and pricing details.
06. Pomegranate Health
Advertises an included-care semaglutide starting offer with no membership fee. Request the full selected term and later charge to make the comparison complete.
Pomegranate Health lists compounded semaglutide from $119 per month with care, medication, and shipping included and no additional membership fee. The product page does not establish every plan term or renewal price.
Ask for the pharmacy’s actual name and state license, along with a complete quote. Phrases such as “FDA-registered” or “FDA-licensed” on a marketing page are not evidence that a compounded medication is FDA-approved.
Check the official Pomegranate Health program page for the current offer and conditions. Our Pomegranate Health alternatives comparison examines other care models.
The current NiceRx baseline
NiceRx lists semaglutide at $99 for the first month, then $199 per month, and tirzepatide at $199 for the first month, then $299. It says medication, provider access, and shipping are included.
The weight-loss program describes self-pay care and says it does not accept insurance. Prescribing follows a clinical assessment, with access limited by the patient’s state and the selected treatment.
Budget with the ongoing price, not just the first month. The page directs cancellation requests to email and says dispensed medication cannot be returned; confirm the order stage and next renewal separately.
The details that decide this comparison
Use NiceRx’s listed $199 ongoing semaglutide rate or $299 tirzepatide rate for a recurring-cost comparison. The introductory figures describe only the first month.
Ask whether an alternative accepts transfers under its starter promotion. Being a new customer is not necessarily the same as starting a medicine for the first time.
Confirm the cancellation request deadline and whether the current prescription has been dispensed. Future billing and returns of dispensed medication are different issues.
Keep the treatment distinction clear
An FDA-approved branded medicine and a compounded preparation have different regulatory status. Compounded drugs are not FDA-approved. Trials of an approved product do not prove that every compounded version has the same performance.
Ask the prescribing professional why the exact product is appropriate for you, and identify the dispensing pharmacy. A price, a website’s appearance, or a place in this list cannot establish personal suitability. Our guide to compounded drugs and FDA approval explains the distinction.
Before you make a change
For a simple budget, write the first payment, the next three payments, and any existing cancellation obligation in one list. This can reveal whether switching only postpones a higher recurring cost.
Keep the clinical decision separate from promotion eligibility. A prescriber should determine the appropriate medicine and instructions using your treatment history.
Sources & research notes
Checked September 21, 2026. Provider pages document the provider’s own statements; they do not independently establish treatment safety or results. This is desk research, not a product test or clinical review.
- CoreAge Rx: official treatment overviewProvider-published information · Checked September 21, 2026
- CoreAge Rx: current sale offerProvider-published information · Checked September 21, 2026
- CoreAge Rx: plan billing explainedProvider-published information · Checked September 21, 2026
- CoreAge Rx: contact and professional-entity disclosuresProvider-published information · Checked September 21, 2026
- CoreAge Rx: purchasing processProvider-published information · Checked September 21, 2026
- Brightmeds: official program, pricing, and care detailsProvider-published information · Checked September 21, 2026
- Ivy Rx: official program, pricing, and care detailsProvider-published information · Checked September 21, 2026
- No Insurance GLP-1 and GLP-1/GIP Medication Cost CalculatorProvider-published information · Checked September 21, 2026
- Online Medical Weight Loss Program | Mochi HealthProvider-published information · Checked September 21, 2026
- Mochi: August 2026 dose-based pricingProvider-published information · Checked September 21, 2026
- Contact us | Mochi HealthProvider-published information · Checked September 21, 2026
- Pomegranate Health: official program, pricing, and care detailsProvider-published information · Checked September 21, 2026
- NiceRx: official program, pricing, and care detailsProvider-published information · Checked September 21, 2026
- FDA: concerns with unapproved GLP-1 drugsRegulatory / public agency · Checked September 21, 2026
- FDA: risks of compounded drugsRegulatory / public agency · Checked September 21, 2026
Read our methodology · Commercial disclosure · Request a correction